The MarketWatch News Department was not involved in the creation of this content. Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo ...
NOVATO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE) today announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis ...
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results